Targeted immunotherapy of cancer with CAR T cells: Achievements and challenges

Grazyna Lipowska-Bhalla, David E. Gilham, Robert E. Hawkins, Dominic G. Rothwell

    Research output: Contribution to journalArticlepeer-review


    The adoptive transfer of chimeric antigen receptor (CAR)-expressing T cells is a relatively new but promising approach in the field of cancer immunotherapy. This therapeutic strategy is based on the genetic reprogramming of T cells with an artificial immune receptor that redirects them against targets on malignant cells and enables their destruction by exerting T cell effector functions. There has been an explosion of interest in the use of CAR T cells as an immunotherapy for cancer. In the pre-clinical setting, there has been a considerable focus upon optimizing the structural and signaling potency of the CAR while advances in bio-processing technology now mean that the clinical testing of these gene-modified T cells has become a reality. This review will summarize the concept of CAR-based immunotherapy and recent clinical trial activity and will further discuss some of the likely future challenges facing CAR-modified T cell therapies. © 2012 Springer-Verlag.
    Original languageEnglish
    Pages (from-to)953-962
    Number of pages9
    JournalCancer Immunology, Immunotherapy
    Issue number7
    Publication statusPublished - Jul 2012


    • Cancer
    • Chimeric antigen receptor
    • Gene modification
    • Immunotherapy
    • T cell


    Dive into the research topics of 'Targeted immunotherapy of cancer with CAR T cells: Achievements and challenges'. Together they form a unique fingerprint.

    Cite this